Stryker Corporation (SYK)

Investment Committee Summary

Investment Thesis

At 315 dollars, Stryker trades on roughly 21 times forward earnings and about 5.3 times enterprise value to revenue, a clear premium to a medtech peer median near 15 times. The market is paying for durable mid-single-digit procedure growth, a widening operating margin, and the Mako-led innovation cadence continuing to take orthopaedic share. Our engine broadly agrees on the trajectory but not on the price. Base-case earnings of about 15 dollars per share on 6 percent growth and a 25.7 percent operating margin, capitalised at 21.8 times, yield a probability-weighted target of 315 dollars, essentially the spot. The independent discounted-cash-flow anchor sits lower near 268 dollars, so the valuation leans on the multiple rather than on cash flow. That gap, combined with a Monte Carlo probability of upside below 40 percent, drives the HOLD: the fundamentals are sound but already discounted. The single most damaging risk is GLP-1 adoption durably deferring elective orthopaedic procedures, which would compress both volume growth and the premium multiple at once.

The dashboard below is the whole argument on one page: spot ($328) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The highest-probability bear mechanism is the structural-impairment path, at 20 percent. Widening GLP-1 use durably suppresses obesity-linked joint degeneration and defers a meaningful share of elective hip and knee procedures, the profit core of the orthopaedics franchise. Volumes turn negative rather than merely slowing. Hospitals, facing their own budget pressure, extend a reimbursement and pricing reset that Stryker cannot offset through mix. Negative operating leverage then drags the operating margin toward 20 percent, and the market re-rates a former compounder to a distressed 13 times earnings. Earnings and the multiple fall together, and the target lands below the 52-week low of 281 dollars. This is a slow, evidence-generating thesis, observable in successive elective-volume prints.

Key Debate

P/E Multiple explains 69% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

What the Market Is Pricing In

At the current price, the market pays 21.8× consensus forward EPS, vs the house DCF terminal 18.0×, and a peer median 15.3×. The house DCF sits 19% below spot, so the market is pricing in more than the house case — roughly 1.9pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily event-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' downside ($139) to a 'Bull — Re-Rate' bull case ($550); the probability-weighted blend (PWEV $314) is -4% versus spot.

Share-count charge: none applied. The probability-weighted value above is the gross per-share figure — no annual dilution is deducted — stock-based compensation runs at 1.0% of revenue; free cash flow net of SBC is $4.04B. SBC is therefore disclosed, not charged: read the per-share figures as before dilution.

Scenario rationale — the driver path behind every target:

• Structural — Reimbursement / Competition / GLP-1 Procedure Hit (20%, $139). Structural impairment — reimbursement / competition / GLP-1 procedure hit: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• Hospital-Capex / Utilization Recession (17%, $235). Cyclical downturn — procedure volumes + product-innovation cycle + hospital capital spending weakens for 1–2 years before normalising.
• Base — Procedure Volume + Innovation (35%, $328). Mid-cycle — normalised procedure volumes + product-innovation cycle + hospital capital spending; disciplined capital allocation; steady returns.
• Growth — New-Product Cycle / Penetration (20%, $438). Upside — new-product cycle + penetration lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Re-Rate (8%, $550). Upside tail — sustained tight conditions or a structural re-rate on new-product cycle + penetration.

Valuation Triangulation

Three weighted anchors — an intrinsic dcf, a scenario-weighted pwev and a monte carlo median (student-t + regime switching) — read them with their basis in mind. The Monte Carlo, the DCF terminal and any peer re-rate key off a market multiple, so they are not fully independent; only discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat three numbers as three independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts, peer P/E re-rate are not computed, so 25% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $283 and 35% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (69% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 18.0x terminal FCF multiple → $266. This anchor is deliberately the heaviest (47%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median EV/Revenue multiple implies $226; the peer-median forward P/E is 15.3x, but the engine carries no P/E-implied price for this name (no forward-EPS basis at the peer step). A premium is only justified by superior growth/margins; otherwise it is multiple risk. Excluded from the weighted blend — shown only as a market cross-check.

Across all anchors the spread is 31% of the median — moderate (healthy method disagreement — read the blend with care).

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Medical Devices & Equipment multiple (AI re-rating) (base 21.0x)

Peer Quality & Weighting

Quality-weighted forward P/E: 17.8× (simple median 15.3×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $281–$402, centre $336 (+2% vs spot); spot sits at the 39th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

That ratio compares triangulated upside against the probability-weighted bear target, not the extreme tail; with a leg missing it is withheld rather than computed from a magnitude. Bull case (Bull — Re-Rate): $550.

Company Overview & Business Model

Stryker Corporation — HEALTHCARE · MEDICAL DEVICES. Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

How it makes money.

Edge. Wide moat — Stryker's moat is a genuine razor-and-blade franchise — the Mako robotic installed base locks in high-margin implant/consumable pulls plus surgeon switching costs and a diversified med-surg portfolio; this durability justifies a premium terminal multiple, but if procedure growth slows to low-single-digit and Mako's share-gain flywheel matures, the terminal multiple should compress from ~21x toward the ~15x medtech peer median rather than expanding.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1% of revenue; cash conversion (OCF/NI) 155% — cash-backed.

Competitive Moat

Moat sources:

• Mako robotic-arm installed base creating recurring implant/consumable pull-through
• Orthopedic-surgeon training/switching costs and hospital procedure standardization
• Diversified MedSurg/Neurotech portfolio (defensive breadth, cross-sell)
• Regulatory (FDA/CE) approval barriers and clinical-evidence moat around implants

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q2): management +0.51 vs analyst floor +0.00 → delta +0.51 (n=27 mgmt / 19 Q&A; 70th pctile across the S&P book, z +0.6).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 1433 articles): avg ticker sentiment +0.10 (bullish 17% / bearish 8%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Catalyst Calendar

• 2026-09-20 (~27d) — Major orthopedic clinical/industry congress data readout (authored)
• 2027-01-25 (~154d) — Investor Day — organic-growth durability & margin-expansion targets (authored)

Forecast Track Record

• EPS surprise: beat 88% of the last 8 quarters; average surprise +1.3%.
• Prior-forecast backtest (13 snapshots, 2026-06-27→2026-08-20): directional hit-rate 69%; mean predicted -4.6% vs realised -0.8%. Disconfirming track record is reported, not suppressed.

Catalyst Timeline

5 catalysts in the next 90 days (of 14 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 0 bearish / 0 caution rules triggered of 6 evaluable (0 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is a portfolio-management signal and does not modify the published research rating.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Organic constant-currency revenue growth < 0.025 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Adjusted operating margin < 0.243 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Mako / robotic installations and utilisation trend declining 0 (2 consecutive prints). A sustained fall in robotic placements or per-system utilisation would confirm the innovation-led penetration engine is stalling, removing the differentiator behind the premium multiple.
• Elective orthopaedic procedure volume growth < 0.0 (2 consecutive prints). Outright declines in elective orthopaedic volumes would validate the GLP-1 procedure-deferral mechanism central to the structural-impairment path.
• Net-debt / EBITDA > 3.0 (single event). (rationale withheld pending re-authoring — frozen figure or verdict)
• Free-cash-flow conversion of net income < 0.75 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)

Fact / Inference / Speculation

• FACT: Spot $328; 52-week range $281–$402; engine rating HOLD; house target $315 (-4%). (source: Alpha Vantage 2026-08-24, 25 August 2026)
• INFERENCE: Triangulated FV $286 (-13% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

64.3/100 (confidence band 53.2–75.5), 72nd percentile of 858 covered names (as of 2026-08-24). Weighted composite under config ros-1.19.0 — every component and its inputs below.

Missing inputs (macro tailwinds) are excluded and the remaining weights renormalised; the confidence band widens accordingly.

Score history: 64.0 → 64.0 → 64.5 → 64.0 → 64.0 → 64.5 → 64.1 → 64.1.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $313.98.

Factor Exposures

Cross-sectional percentiles over 858 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Market interaction: correlation vs SPY +0.38, vs QQQ +0.25 (trailing ~1y daily returns).

Options Intelligence

Preferred structure: Long Stock. The selector reads the equity view (direction) and the volatility surface — nothing here re-prices the chain.

• no directional edge and options are cheap — options add little; hold the stock
• Direction neutral from the overlay conviction/rating (read-only input).
• IV/RV at the 8th percentile of the cross-section → low vol bucket. This is the measure that selects the structure above: it ranks how rich this name's implied vol is against its own realised vol, relative to other names.
• Reported alongside and not used to select: this name's own ATM IV sits at the 75th percentile of its own month-end history (decile 8). The two measures disagree here — vol is high for this name by its own history while its options are not unusually rich against its realised vol. Where they diverge, the cross-sectional measure is the one acting.
• IV term structure is in contango (longer-dated richer, slope +2.9pp) — favour longer-dated ownership (LEAPS) or calendars that are long the cheaper front.
• No live-chain Long Stock was priced for this name — shown as the indicated strategy; size against a freshly pulled chain.

IV term structure (contango, slope +2.9pp): 25-DTE 29% · 116-DTE 30% · 389-DTE 32%

No live-chain Long Stock was priced for this name — shown as the indicated approach; size against a fresh chain.

Alternatives: . IV rank shown via the name's own monthly IV history (advisory); structure selected on the cross-sectional IV/RV percentile. Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Position Sizing Framework

Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Options Overlay

A defined-risk way to express the HOLD equity view. Chain as of 2026-08-24 — end-of-day marks — indicative, not executable quotes.

Market signals — ATM IV 28.8% (subdued regime) · expected move ±5.7% (2026-09-18) · put/call OI 0.54 · ATM Δ 0.49 / Θ -0.21 / ν 0.34. Direction: NEUTRAL (implied return -12.9% to triangulated fair value $285.55).

Covered Call (if held) (Income / neutral) — Short 350 C · 2026-09-18 · premium $2.55 · yield 0.8% · priced from the listed chain (EOD marks)

Converts a near-fair holding into income by agreeing to sell at a higher strike — worth weighing when upside looks limited near fair value and being called away is acceptable. Illustrative — no outcome is implied or guaranteed.

Put Spread (income) (Income / would-own) — Short 300 P / Long 280 P · 2026-10-16 · net $2.25 · net entry $297.75 · yield 0.7% · RoR 13.0% · max loss $17.75 · priced from the listed chain (EOD marks)

Gets paid to wait for a lower entry, with the tail capped: the sold put collects premium while the cheaper long wing below it caps the maximum loss at the spread width — a defined-risk alternative to a naked cash-secured put.

Protective Collar (if held) (Hedge) — Long 300 P / Short 360 C · 2027-03-19 · net $4.1 · floor -8.0% · cap +10.0% · priced from the listed chain (EOD marks)

For a holder who wants to stay invested but cap risk: the sold call funds most of the protective put, fencing the position into a band — a way to ride out a de-rating without selling.

Indicative options structures — a defined-risk expression of the equity view, model-and-market illustrated from the last-close chain. NOT personalised advice or an executable quote; premiums, IV and greeks move intraday. Options carry the risk of total loss of premium. Not a registered financial adviser.

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies -4% vs spot
• Monte Carlo median implies -14% vs spot
• DCF fair value implies -19% vs spot
• Bear case (Structural — Reimbursement / Competition / GLP-1 Procedure Hit) downside is -58% vs spot
• Net: the valuation anchor itself sits 12.9% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $26B + PV(terminal) $89B = EV $115B; − net debt $12.4B → equity $103B ÷ diluted shares $0.39B = $266/share (exit-multiple terminal).

• Gordon terminal at 2.5% → $255/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 34% vs WACC 8.5% → above WACC — the build is value-creative.

Peer set

Implied prices at the peer medians: EV/Rev → $226 (no P/E-implied price — no forward-EPS basis at the peer step).

Weighted fair-value math

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Revenue CAGR ±3pp (79.0); Terminal × ±15% (69.0); Op margin ±3pp (65.0); WACC ±1pp (25.0); Capex intensity ±15% (12.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

DCF: WACC 8.5%, terminal multiple 18×, FY+5 revenue $32B. Triangulation leans 47% on DCF, 33% on PWEV, 20% on the Monte Carlo median.